参考文献/References:
[1] WOLF M M,KIMRYN R W,BECKERMANN K E.Modeling clear cell renal cell carcinoma and therapeutic implications[J].Oncogene,2020,39(17):3413-3426.
[2] ZHAO J,EYZAGUIRRE E.Clear cell papillary renal cell carcinoma[J].Arch Pathol Lab Med,2019,143(9):1154-1158.
[3] CHOWDHURY N,DRAKE C G.Kidney cancer:An overview of current therapeutic approaches[J].Urol Clin North Am,2020,47(4):419-431.
[4] WILLIAMSON S R.Clear cell papillary renal cell carcinoma:An update after 15 years[J].Pathology,2021,53(1):109-119.
[5] QIN S,SHI X,WANG C,et al.Transcription factor and mirna interplays can manifest the survival of ccRCC patients[J].Cancers(Basel),2019,11(11):1668.
[6] 吕瑜玫,陈丹,朱桥,等.宫颈癌患者血清微小核糖核酸-381、微小核糖核酸-145水平变化及与临床病理参数相关性分析[J].陕西医学杂志,2023,52(7):925-928.
[7] SHI N,SHAN B,GU B,et al.Circular RNA circ-PRKCI functions as a competitive endogenous RNA to regulate AKT3 expression by sponging miR-3680-3p in esophageal squamous cell carcinoma[J].J Cell Biochem,2019,120(6):10021-10030.
[8] CAI K,CHEN S,ZHU C,et al.FOXD1 facilitates pancreatic cancer cell proliferation,invasion,and metastasis by regulating GLUT1-mediated aerobic glycolysis[J].Cell Death Dis,2022,13(9):765.
[9] 中国医学论坛报.标准?方案?指南——美国国立综合癌症网络肾癌指南2015.V.3版更新解读[J].中国全科医学,2015(22):2731.
[10] ZHANG Y,SUN Z,MA H,et al.Prediction of Fuhrman nuclear grade for clear cell renal carcinoma by a multi-information fusion model that incorporates CT-based features of tumor and serum tumor associated material[J].J Cancer Res Clin Oncol,2023,149(17):15855-15865.
[11] BAHADORAM S,DAVOODI M,HASSANZADEH S,et al.Renal cell carcinoma:An overview of the epidemiology,diagnosis,and treatment[J].G Ital Nefrol,2022,39(3):2022-2035.
[12] 王元元,张祥林,吕晓虹.CT图像容积纹理分析在肾透明细胞癌病理分级中的应用研究[J].陕西医学杂志,2020,49(3):304-308,312.
[13] ALAGHEHBANDAN R,SIADAT F,TRPKOV K.What's new in the WHO 2022 classification of kidney tumours?[J].Pathologica,2022,115(1):8-22.
[14] HUANG W C,DONIN N M,LEVEY A S,et al.Chronic kidney disease and kidney cancer surgery:New Perspectives[J].J Urol,2020,203(3):475-485.
[15] 王斌,李建,何轩,等.微小RNA-3680-3p在肾癌组织中的表达及对人肾癌细胞ACHN迁移和增殖的影响[J].山西医科大学学报,2019,50(2):154-158.
[16] LI H,RAUCH T,CHEN Z X,et al.The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells[J].J Biol Chem,2006,281(28):19489-19500.
[17] GUO M,LI X,LI T,et al.YTHDF2 promotes DNA damage repair by positively regulating the histone methyltransferase SETDB1 in spermatogonia[J].Biol Reprod,2024,110(1):48-62.
[18] FARIAS E,TERREMATTE P,STRANSKY B.Machine learning gene signature to metastatic ccRCC based on ceRNA network[J].Int J Mol Sci,2024,25(8):4214.
[19] LIU X,WANG F,DU W,et al.ESM-1 mediates cell progression in clear cell renal cell carcinoma by affecting Wnt/β-Catenin signalling pathway[J].Arch Esp Urol,2023,76(4):290-297.
[20] IE Y,LI J,SUO Y,et al,Chen X.Downregulation of miR-3680-3p inhibits the progression of osteoarthritis via targeting OGG1[J].Arch Gerontol Geriatr,2022,100:104626.
[21] PAN H,PENG J,QIAO X,et al.Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis[J].Open Med(Wars),2023,18(1):20230666.
[22] 苟东,王全,刘蓉,等.miR-3680-3p在肾透明细胞癌组织中的表达及与术后复发转移的关系[J].新疆医科大学学报,2023,46(11):1496-1501.
[23] 吴峥,潘腾,王淑彬,等.透明细胞肾细胞癌中FOXD1的表达及其对786-O细胞增殖侵袭、上皮-间质转化的影响[J].临床与实验病理学杂志,2023,39(4):439-444.
[24] 杨虓,陈冉,王晓明.FOXD3-AS1与miR-135a-5p的相互作用及对肾细胞癌细胞增殖、迁移和侵袭的影响[J].解放军医药杂志,2022,34(6):11-16,20.